arimoclomol inn originally codenamed citrate salt formulation experimental drug developed cytrx corporation biopharmaceutical company based los angeles california worldwide rights arimoclomol bought danish biotech company orphazyme european medicines agency ema us food drug administration fda granted orphan drug designation arimoclomol potential treatment niemannpick type c arimoclomol believed function stimulating normal cellular protein repair pathway activation molecular chaperones since damaged proteins called aggregates thought play role many diseases cytrx believes arimoclomol could treat broad range diseases arimoclomol activates heat shock believed act arimoclomol shown extend life animal model well tolerated healthy human volunteers phase study cytrx currently conducting phase ii clinical arimoclomol also shown effective treatment animal model spinal bulbar muscular atrophy sbma also known kennedys arimoclomol discovered hungarian researchers drug candidate treat insulin diabetic complications retinopathy neuropathy nephropathy later compound along small molecules screened development hungarian firm biorex sold cytrx corporation developed toward different direction httpsenwikipediaorgwikiarimoclomol